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BACKGROUND: Blood pressure variability (BPV) is a possible risk factor for adverse cardiovascular 
outcomes and mortality. There is uncertainty as to whether BPV is related to differences in 
populations studied, measurement methods or both.  We systematically reviewed the evidence for 
different methods to assess blood pressure variability (BPV) and their association with future 
cardiovascular events, cardiovascular mortality and all-cause mortality. 
 
METHODS: Literature databases were searched to June 2019. Observational studies were eligible if 
they measured short-term BPV, defined as variability in blood pressure measurements acquired either 
over a 24-hour period or several days. Data were extracted on method of BPV and reported association 
(or not) on future cardiovascular events, cardiovascular mortality and all-cause mortality. 
Methodological quality was assessed using the CASP observational study tool and data narratively 
synthesised.  
 
RESULTS: 61 studies including 3,333,801 individuals were eligible. BPV has been assessed by various 
methods including ambulatory and home-based BP monitors assessing 24-hour,  ‘day-by-day’  and 
‘week-to-week’ variability. There was moderate quality evidence of an association between BPV and 
cardiovascular events (43 studies analysed) or all-cause mortality (26 studies analysed) irrespective of 
the measurement method in the short- to longer-term. There was moderate quality evidence 
reporting inconsistent findings on the potential association between cardiovascular mortality, 
irrespective of methods of BPV assessment (17 studies analysed).  
 
CONCLUSIONS: An association between BPV, cardiovascular mortality and cardiovascular events 
and/or all-cause mortality were reported by the majority of studies irrespective of method of 
measurement. Direct comparisons between studies and reporting of pooled effect sizes was not 
possible.  
 







Blood pressure variability (BPV) has been assessed through various methods across a variety of 
populations and setting. 
 
BPV is associated with cardiovascular events, cardiovascular mortality and all-cause mortality. 
 








Blood pressure varies physiologically in response to changes in demand that accompany normal 
activities and in predictable trends driven by the circadian rhythm.[1] Fluctuations in blood pressure 
increase with age even in normotensive individuals.[2] This variation in blood pressure is known as 
blood pressure variability (BPV). There is growing interest in BPV as a risk factor for adverse 
cardiovascular outcomes and mortality.[1,2] However, studies to date have shown conflicting results, 
which are potentially related to differences in populations studied and measurement methods.[1-6]  
 
There remains uncertainty on the choice of an optimal method to measure BPV. Blood pressure 
variability can be analysed using either time domain or frequency domain analysis. Frequency domain 
analysis requires signal processing skills with which to transform blood pressure signals into different 
frequency components and to quantify the variance or “power” at each specific frequency. Time 
domain analysis, which is widely used, evaluates the variability of blood pressure measurements over 
any specified time period. Various measurement methods have been employed to determine BPV 
using time domain analysis. The most commonly applied BPV measurement methods include standard 
deviation (SD), coefficient of variation (CoV) and average real variability (ARV). Newer methods include 
individual residual variation (IRV), variation independent of the mean (VIM), maximum-minimum 
difference (MMD), and BPV ratio. While some studies used only one method,[3,4,7-15] many used 
more than one method.[16-22]  
 
Despite increasing evidence linking increased BPV with poorer outcomes,  the pathophysiological 
process underlying BPV and its relevance in clinical practice remain unclear. Changes in BP between 
measurements either within the day, day to day or visit to visit may occur from physiological insults 
from illness or medications, or impaired haemodynamic regulatory systems which is in turn a 
reflection of overall health status [23]  Determination of BPV may therefore be a useful biomarker or 
prognostication in clinical practice [17,18] Furthermore, the presence of large variations in BPV is likely 
to influence blood pressure treatment targets and well as clinical decisions on frequency of BP 
monitoring, which should be individualized in older adults.[24] Therefore a better understanding of 
the relationship between BPV and cardiovascular and mortality outcomes as well as the available 
methods of measurements of BPV and their individual relevance in practice may potentially assist in 





Few previous systematic reviews have been published investigating the impact of BPV on 
cardiovascular outcomes.[22,23,25] There has been limited assessment of the differences in 
cardiovascular outcomes distinguishing the method of BPV measurement. The potential association 
between different measures of BPV has been previously highlighted.[23] However several new studies 
have been published which may change the interpretation of these previous studies. The aim of this 
systematic review was therefore to investigate the association of BPV, stratified by various methods 
of BPV measurement, with cardiovascular events, cardiovascular mortality and all-cause mortality. 
 
MATERIALS AND METHODS 
 
 
This systematic review was reported in accordance with the Preferred Reporting Items for Systematic 
review and Meta-Analysis (PRISMA) guidelines.[26] The PRISMA checklist is Supplementary File 1. The 




A systematic literature search of MEDLINE, EMBASE, OpenGrey and the ClinicalTrials.gov databases 
was conducted. The search was limited to human studies published in English between 2004 and the 
search date (3rd June 2019). A 2004 search strategy start date was selected to provide a contemporary 
analysis of participants managed with current therapies and health services.[23] The search strategy 
is presented in Supplementary Table 1 and tailored for each of the search databases. To augment the 
principal search strategy, a forward citation search was performed for all included studies using the 
Scopus database. Secondly, a backwards citation search was also conducted through a review of all 
included study reference lists. Finally, corresponding authors of all potentially eligible studies were 
contacted and asked to identify any previously omitted studies. No additional citations were identified 
through these approach.   
 
Identification of Studies 
 
Two investigators (AA-F/TS) screened papers identified from the search for inclusion, firstly by title 







Studies were included if they were: 
 
Population: people who were community-dwelling, hospital or institutional-living. No age restriction 
was made. 
 
Intervention: measurement of BPV over 24-hours or longer and followed-up adult subjects for more 
than a year for cardiovascular events, cardiovascular mortality or all-cause mortality. Accordingly, 
studies which assessed only visit-to-visit BPV or beat-to-beat BPV were excluded. Studies assessing 
‘nocturnal dip’ and ‘morning surge’ variables were excluded as physiologically discrete from random 
BPV. We did not control by methods of BPV as we wished to assess the impact of methods of 
assessment on BPV. 
 
Outcome: Cardiovascular events were grouped as composite outcomes including myocardial 
infarction (MI), stroke, first hospitalisation or diagnosis of heart failure, coronary revascularisation, 
coronary artery bypass graft, peripheral vascular disease, renal failure with dialysis, transient ischemic 
attack, acute aortic aneurysm dissection or grafting and angina. As recommended by Mena et al,[16] 
coronary artery disease was defined by any of the following: MI diagnosed on the basis of at least two 
of three standard criteria (typical chest pain, electrocardiographic QRS changes, and positive ischemia 
serum markers) or angina pectoris defined by chest pain, coronary angiography showing 
hemodynamic significant obstructions or revascularisation procedures. Stroke was diagnosed on the 
basis of rapid onset of localising neurological deficit lasting 24 hours in the absence of any other 
disease (or lasting less than 24 hours for transient ischemic attack). Congestive heart failure was 
diagnosed using McKee criteria.[27] 
 
Design: Review articles, poster abstracts, or otherwise non-observational studies were excluded, as 
were specific cohorts such as those comprised of patients on dialysis or with previous stroke. Studies 
which investigated the same databases or geographical area were all included in the review. 
  
Where papers reported the same study or data from the same cohort two or more times, these were 







Two pairs of two reviewers (AA-F/TS and JS/AE) independently extracted data into a pre-specified data 
extraction table. Data extracted included: study date and location; cohort size, co-morbidities, age, 
gender; method of assessing blood pressure; method of assessing outcomes of interest. Data were 
collected on the association between BPV (24-hours, day-time, night-time) and cardiovascular 
outcomes. Methods of calculating BPV that were deemed eligible included categorical assessment 
(high versus low variability) as there are currently no ‘gold standards’ for defining or measuring BPV, 
and therefore thresholds are arbitrary at present,[28] SD of blood pressure, and CoV (SD/mean), in 
addition to the ARV. The ARV was defined as the absolute difference of consecutive blood pressure 
readings, thereby accounting for the order in-which measurements were obtained.[6]  Cardiovascular 





The quality of the studies was assessed using a modified version of the Critical Appraisal Skills 
Programme (CASP) checklist for cohort studies.[29] For each question, a score of one denoted good 
performance in that area and zero denoted an unclear method or failure to meet the criterion, 
resulting in a total score for each paper. Each study was reviewed by two reviewers independently 
(AA-F/TS and JS/AE). 
 
Disagreements in respect to study eligibility and inclusion, data extraction and quality assessment 
were resolved through discussion until consensus was reached. Any further disagreements were 
resolved by the arbitration of a third reviewer (PKM).  
 
A judgement on the quality of the evidence was made specifically by assessing the CASP items and 
specifically Items 5, 6 (confounding) and 7, 8 (follow-up completion and duration) which were deemed 
the most important items for this study design by the research team. Quality of evidence was termed 




The between-study heterogeneity was assessed though analysis of the data extraction tables. This 




under-investigation. As a result, it was deemed inappropriate to undertake a meta-analysis of the 
data.  
A narrative analysis reporting hazard ratios was therefore adopted to answer the research questions 
on different methods of assessing BPV and adverse cardiovascular outcomes. Blood pressure 
measurements for BPV estimation were obtained through both ambulatory blood pressure 
monitoring (ABPM) over 24-26 hours as well as home blood pressure monitoring (HBPM) using 
automated devices over 7-28 days. In BPV obtained from ABPM for instance, blood pressure 
measurements are usually obtained every 15 minutes during the daily time (16 hours) and 30-minutes 
at night-time (eight hours). Thus, within 24 hours, there should be around 80 blood pressure 
measurements for each subject. Multiple formulae are then used to calculate variability. The simplest 
formula is SD.  We presented three methods of estimation of BPV was presented: SD, CoV and ARV. 
The association between these different assessment methods and the end-points (cardiovascular 
events/cardiovascular mortality/all-cause mortality) was investigated. This was reported by one of 
three timepoints i.e. short- (up to 24 hours), medium (24 hours to one-week) and long-term (greater 
than one-week). Through this, short-term referred to beat-to-beat and within and between hour 
measurements, medium-term as between day/night or between days (as obtained from HBPM) and 





The search strategy identified 4259 unique citations. After title and abstract screening, 362 full-texts 




A summary of the included study characteristics is presented in Supplementary Table 2. Included 
studies were predominantly cohort studies, performed either prospectively or retrospectively. This 
included data from 3,333,801 individuals. Mean ages of participants ranged from 47.1 years [30] to 85 
years.[31] Mean percentage of females in study cohorts was 45.0% (SD: 19.2) with four studies 
excluding females [2,6,32,33] and one study excluding males.[34] Follow-up interval ranged from 12 
months [9,35,36] to 20 years.[37] Thirty-nine studies were conducted in a hospital setting, 




community.[1-3,,5,6,9,12,13,16,20,21,30,37,51,62,63,65-68,70] - This was not documented in one 
paper.[17]  
 
Forty-two studies specified a specific comorbidity(ies) which were used as eligibility criteria. When 
used, this was hypertension in 24 studies, [10-12,14-16,19,33,35,38,4-
42,45,46,51,54,56,59,60,65,66,69,70] type 2 diabetes in five studies,[4,44,58,62,64] history of or risk 
factors for cardiovascular disease in five studies,[39,48,49,-50,68] hypertension with coronary artery 
diseases in one study,[38] five studies recruited participants who had had an ischaemic 
stroke,[25,36,47,57,61] whilst two studies recruited people with previous transient ischaemic attacks 
(TIA) or non-disabling stroke.[21,57] One study only excluded participants with a previous stroke.[13] 
Hsu [37] only recruited normotensive participants. The presence of previous and current medical 
conditions was not specified in 19 studies.[1,2,3,5,6,8,9,13,17, 21,30,31,34,43, 52,53,55,63,71] 
 
Seventeen (28%) studies separately examined cardiovascular mortality as an 
endpoint.[2,6,13,16,19,21,25,46-49,53,62,65-67,69] Twenty-six (43%) studies investigated all-cause 
mortality either as a primary or secondary outcome. [2,5,6,9,13,15,16,19-21,25,42,43,47-
49,50,52,53,59,62,64-67,69] Forty-four studies (72%) had a composite ‘cardiovascular events’ 
endpoint which included fatal and non-fatal events.[1,3,4,6,8-12,14,17,19,20,25,30-41,43-
45,48,50,51,53-55,57,58,60,61,63,64,67,69-71]  Twenty-two studies (37%) had a separate outcome 
for incident stroke.[6,7,15,25,34,36,38-41,44,45,47,48,50,51,53,54,59,63,68,70] 
 
One study assessed for the occurrence of left ventricular abnormalities.[60] One study assessed 
specifically for chronic heart failure[66] and one assessed chronic heart disease.[53] One study 
assessed cardiovascular risk.[7] One study post-stroke functional outcome.[61] Asayama et al [19] 
assessed lacunar infarct as their outcome, detected by computed tomography or magnetic resonance 
imaging. 
 
Thirty studies (49%) measured blood pressure over 24 to 26 hours (short-term) using ambulatory BP 
monitors, [1-6,8-12,14-17,33,35-37,40,42,52,54,57,60,61,63,65,67,69]; in 34 studies (56%), ‘day-by-
day’ variability was determined in participants who self-measured blood pressure for 7-28 days with 








The results of the critical appraisal are presented in Supplementary Table 3. The evidence was judged 
to be of moderate quality overall. Whilst included studies recurrently presented strengths including 
clearly posing a defined research question (100%), recruiting their cohorts in an acceptable and 
defined approach (93%), measuring BPV accurately (85%) and then accurately assessing 
cardiovascular outcomes (74%), the studies less consistently identified important confounding factors 
(46%), nor accounted for these sufficiently in their adjusted analyses (51%). Subject follow-up was 
determined as sufficient in 44 studies (72%) and by duration in 44 studies (72%). The results were 
clearly presented in 44 studies (72%),suitable to implement to general population in 27 studies (44%) 




Due to the large degree of heterogeneity in methods of BPV measurements as well as the variations 
of types of BPV measured in both ambulatory, home and office blood pressure measurements, it was 
not possible to determine individual effect sizes or to report pooled effect sizes.  Therefore, the 
number of studies employing each method as well as the numbers with positive or negative findings 
were tabulated in detail to provide a source of reference for future researchers Supplementary Table 
4. A summary of the number of studies reporting each outcome associated with BPV and the number 
of participants included in these studies are summarised in Table 1, with fuller presentation in 
Supplementary Table 4. 
 
Ambulatory Blood Pressure Measurements 
 
Cardiovascular Events 
Cardiovascular events were reported in 22 studies, 17 of which reported the presence of associations 
with at least one systolic BPV (SBPV) variable, while five studies did not record any associations in any 
SBPV. Six studies reported the presence of associations with diastolic BPV (DBPV) and cardiovascular 
events, while four studies reported no association. SD was employed by 22 studies to estimate SBPV 
of which 17 demonstrated positive results, [1,3,4,6,8,9,11,12,14,17,33,35,37,40,57,60,69] while five 
were negative.[ 10,36,54,61,63,] Ten studies also evaluated SD-DBPV of which six [6,8,11,17,37,69] 






Cardiovascular mortality was reported for medium-term BPV estimations using ABPM for six 
moderate-quality studies. Three found associations with SBPV and three did not find any associations. 
Five studies which investigated DBPV showed significant associations and only one showed the 
absence of association. All five studies used SD, one used CoV and two used ARV. Of the five studies 
which reported SD-SBPV for ABPM, two were positive [67,69] and four negative.[2,6,16,65] Five 
studies which reported SD-DBPV were positive [6,16,65,67,69] while one was negative.[2] One for 
CoV-DBPV [69] was negative, and the ARV studies reported both SBPV and DBPV of which both were 
positive.[6,67]  
 
Five studies evaluated short-term 24-hour BPV, all used SD-SBPV, from which one was positive [69] 
and four negative [2,6,16,65]. Of the studies which used SD-DBPV, three were positive [6,65,69] and 
two negative [2,16]. CoV was used for 24-hour BPV by one negative study for DBPV [69]. Two studies 
used ARV for 24-hour SBPV and DBPV with positive associations for both.[6,67] Four studies 
investigated the above for cardiovascular mortality using ABPM. Day-time SBPV was positive for one 
study [67] and were negative for the rest three studies,[2,16,69] and DBPV positive for three studies 
[16,67,69] and negative for one.[2] One study was positive for both SBPV and DBPV at night[69] and 




Eleven studies evaluated all-cause mortality for medium-term ABPM derived BPV. All studies reported 
SBPV and nine reported DBPV. Significant associations were reported by six for SBPV and seven for 
DBPV. Nine used SD, four were positive for SBPV and six for DBPV. Of the 11 studies, six evaluated 24-
hour SBPV, one was positive [69] and five negative,[2,16,42, 52,65] while seven evaluation 24-hour 
DBPV, with three positive [6,65,69] and four negative [2,16,42,52] results. Six studies evaluated either 
medium-term day-time or night-time BPV, two studies were positive for day-time SBPV [42,67] and 
three for day-time DBPV [16,42,67], three studies were negative for SBPV for both day and night-time 
[2,69] but positive for both day and night-time DBPV.[16] One study was positive for day-time SBPV 
and DBPV and negative for night-time SBPV and DBPV.[42] One study was negative for day-time SBPV 
and DBPV and positive for night-time SBPV and DBPV.[69] One study which only used night-time SBPV 
was positive.[15] Only one short-term study used CoV, of which one was negative for SBPV over 24-
hours.[15]  Three moderate-quality studies used ARV measured over short-term, two were positive 
for both 24-hour SBPV and DBPV [6,9] and one which only evaluated 24-hour SBPV was negative. The 





Day-to-day or Visit-to-visit Measurements 
 
Cardiovascular Events  
Twenty-seven studies evaluated SBPV in day-to-day or visit-visit measurements for cardiovascular 
events. Both SD and ARV were utilized by one study which evaluated morning, evening, daily and 
morning to evening variations.[20] This reported significant associations in SBPV and SBPV using both 
SD and ARV for morning measurements, SD-DBPV, ARV-SBPV and ARV-DBPV more morning 
measurements and ARV-DBPV for morning to evening measurements.[20]  
 
Twenty-three studies used SD to determine day to day or visit to visit BPV. Twenty studies reported 
significant associations in SD-SBPV alone,[8,20,30,31,34,36,39,41,43-45,,48,50,51,53,55,61,64,70,71] 
while four found significant associations in SD-DBPV alone,[20,45,61,70] two found significant 
associations with both SBPV and DBPV.[61,70] Nine studies employed CoV to evaluate day to day or 
visit to visit CoV-SBPV or CoV-DBPV. All three studies which evaluated both CoV-SBPV and CoV-DBPV 
found  significant associations with cardiovascular events [58,61,70]. Four studies evaluated only CoV-
SBPV, three of which found positive associations [36,39,44] while one did not find any significant 
association.[38] One studies evaluated day to day or visit to visit CoV-DBPV alone and found no 
significant association.[20] Overall, the evidence was graded moderate in quality. 
 
Cardiovascular Mortality 
Ten of the eleven studies which evaluated day to day or visit to visit BPV reported a significant 
association cardiovascular mortality and at least one BPV parameter. Eight studies used SD 
estimations.  Two of the eight studies which estimated morning SD-SBPV had positive results [13,21]. 
Six of the eight studies evaluated day to day or visit to visit SD-SBPV, five of which reported positive 
results [46,48,49,53,66]. Three of the eight studies evaluated day to day or visit to visit SD-DBPV, with 
one reporting a positive association [49] and two found no associations [48,62]. One study used CoV 
for morning SBPV and reported a significant association.[25] Two studies used CoV to estimate day to 
day or visit to visit SBPV and DBPV one [62] reported negative results for both CoV-SBPV and Co-
VDBPV and one [47] a positive association in SBPV but not in DBPV. One study used ARV to estimate 







All-cause mortality was reported in 16 studies, with positive associations in 12 for day to day or visit 
to visit measurements. One study assessed both SD and ARV for morning, evening, daily and morning-
to-evening SBPV and DBPV, with positive associations in all parameters except evening SD-SBPV.[20] 
Three studies used SD alone for morning SBPV, two were positive [13,21] and one was negative.[25] 
Five studies evaluated both SD-SBPV and SD-DBPV for day to day or visit to visit measurements, three 
of which were positive for both [20,49,62] and one for DBPV only [43]. Another four studies evaluated 
only SD-SBPV for day to day or visit to visit measurements, and all four showed positive associations 
with all-cause mortality [50,53,64,66]. Two studies evaluated day to day or visit to visit CoV-SBPV and 
CoV-DBPV, of which one was positive for both CoV-SBPV and Co-V DBPV [62] and one was only positive 
for CoV-SBPV.[47]  One study [59] used only ARV to determine day to day or visit to visit DBPV, which 
was only positive among individuals with systolic blood pressure ≥140mmHg. Overall, the evidence 






There are numerous methods of assessing BPV. Irrespective of method, many more studies have 
reported an association between BPV and cardiovascular events, cardiovascular mortality and all-
cause mortality. It is currently unclear what is the best method to measure BPV.  
 
Our systematic review revealed the presence of considerable diversity in the methods used and 
inconsistencies in the findings of studies that have assessed the relationship between BPV, adverse 
cardiovascular and mortality outcomes.  Some methods of measurement appear to be more effective 
in predicting cardiovascular events. For example, in some studies, measuring the SD of night-time 
diastolic blood pressure tended to out-perform other measures like the SD of day-time 24-hour SD 
blood pressures in predicting cardiovascular events in the given population. However, it was difficult 
to find a sufficient volume of evidence with which to establish these trends with the differences in 
cut-off points or thresholds used, and the multiple subgroups analyses employed by included studies. 
Given these reasons, it remains unclear what the ‘best method’ for assessing BPV is. 
 
High or low BPV may represent an irreversible condition where the blood pressure regulatory system 
is irreparably damaged. This may produce a U- or J-shaped relationship between BPV and 




These may provide more robust estimates of BPV, as individual clinic blood pressure measurements 
are merely a snapshot. There are, however, limited advances beyond ABPM and HBPM to date. New 
technology for continuous measurements is invasive, e.g. requiring arterial line, or not yet fully 
portable and user-friendly.  
 
The mechanisms underlying the relationship between increased blood pressure variability using both 
ambulatory measurements, daily home measurements or office visit measurements with 
cardiovascular endpoints and mortality are unclear. It has been postulated that blood pressure 
variability may be related to arterial stiffness which increases with age and is exacerbated by the 
presence of comorbid hypertension and diabetes.[67] However, this may not necessary account for 
the differences in measurement according to time of day, which may also be driven by hormonal 
factors. Furthermore, the use of medications with shorter half-lives may also account for variations 
within the day, while the introduction or withdrawal of medications may account for differences 
between visits. Nevertheless, increased arterial stiffness, presence of comorbidities, variations in 
hormonal release and use of medications are all related to poorer clinical outcomes, which may 
confound this relationship. Fluctuations in blood pressure may results in poorer outcomes in terms of 
potential increased risk of falls and cognitive deficits with increased exposure to hypotensive episodes 
as well as potential increased risk of haemorrhagic strokes with surges in blood pressure.[72] The 
above proposed mechanisms have not been evaluated in available studies, with further research now 
urgently required. Available evidence does, however, related BPV with target end-organ damage.[71]  
 
This study has some limitations. Firstly, due to the methods adopted in the original studies, it was not 
possible to collect similar data from a sufficient number of studies to meaningfully pool in a meta-
analysis. Therefore, only the number of positive and negative studies were reported rather than 
pooled effect sizes. Similarly, it was not possible to provide a single or range of effect size or summary 
statistics, meaning the approach of presenting positive or negative associations was most appropriate. 
As a novel risk factor, new data collection and analysis methods for BPV continually appear in the 
literature. Incomplete reporting of results and variations in study format also prevented the pooling 
of studies in this review. These difficulties have highlighted the potential for the presence of selective 
reporting in this body of literature, particularly in instances where only significant findings have been 
reported. Similarly, there is a very high risk of selective analysis or outcome reporting in the 
manipulation of data grouping or analysis, for example in the creation of categorical groups of 
variability and whether hazard ratios are calculated per mmHg change or per standard deviation 




heterogeneity to facilitate recommendations based on meta-analyses. Finally, this systematic review 
only investigated cardiovascular mortality and morbidity outcomes and not outcomes such as 
syncope, falls or care home admission. These are all important outcomes particularly for older people 




An association between BPV and cardiovascular events, cardiovascular mortality and all-cause 
mortality, has been reported by most published studies irrespective of method of measurement. It 
was not possible to report pooled effect sizes due to heterogeneity in methods of measurement and 
analysis. Consensus is required on how best to measure BPV given the reported variability in methods, 
in order to enable accurate comparisons in future.  
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Table 1: Number of studies according to measurement method, outcomes, computation methods and presence or absence of association. 
Type of 
measurement 
Outcome n Computation methods ALL 
SD CoV ARV 
+ - + - + - + - 
ABPM Cardiovascular 
outcomes 
38211 13 (19737) 7 (15489) 2 (2541) 2 (1993) 5 
(14457) 
1 (229) 17 (32914) 5 (5297) 
ABPM Cardiovascular 
mortality 
21055 5 (19038) 1 (2017) 0 (0) 1 (486) 1 
(18092) 
0 (0) 5 (19038) 1 (2017) 
ABPM All-cause mortality 27596 7 (22979) 3 (3363) 0 (0) 1 (3433) 3 
(19346) 
0 (0) 8 (24233) 3 (3363) 
ABPM CV events & all-
cause mortality 
55129 18 (38797) 10 
(10117) 
2 (2541) 4 (5912) 6 
(23611) 














50796 7 (45038) 1 (2161) 2 (1176) 1 (2161) 1 (2421) 0 (0) 10 (48635) 1 (2161) 
Day-to-day/Visit-
to-visit 













3 (2855) 10 
(144141) 
4 (6992) 4 
(24167) 






















SD=standard deviation; CoV=coefficient of variation; ARV=average real variability; ABPM=ambulatory blood pressure measurements; CV=cardiovascular. ‘+’ 
indicated number of studies with positive associations, ‘-‘ indicates number of studies with negative associations. Total number of participants involved for 
all studies counted in each cell is indicated in parentheses.  





Supplementary Figure 1: PRISMA flow-chart 
  





























Additional records identified 
through other sources 
(n=6) 




Records excluded  
(n=3897) 
Full-text articles assessed 
for eligibility 
(n=362) 
Full-text articles excluded, with 
reasons (n = 301) 
- Review papers (n=104)  
- Did not measure short-term 
variability, and without CV 
outcome, (n=99) 
- Dipper/non-dipper (n=18) 
- No available data (n=79) 
- Not English language (n=1) 
 






Supplementary Table 1: Search Strategy (MEDLINE used as an example) 
 
 
1. Blood Pressure/  
2. Blood Pressure Determination/  
3. Blood Pressure Monitoring, Ambulatory/ 
4. (blood pressure or bp or sbp or dbp).ti,ab.  
5. OR/1-4  
6. varia*.ti,ab.  
7. (variabilit* or variation?)).ti,ab.  
8. ((between or within) adj3 visit?).ti,ab.  
9. "measure* to measure*".ti,ab.  
10. repeat* measure*.ti,ab.  
11. within subject?.ti,ab.  
12. OR/6-12  
13. AND/5,12  
14. exp animal/ not human/  
15. 13 not 14  
16. incidence.sh. or exp mortality/ or follow-up studies.sh. or prognos*.tw. or predict*.tw. or course*.tw.  





Supplementary Table 2: Characteristics of included studies 
 
 N 





Blood Pressure Measure Mean Follow-up  Outcome 
Arashi [38] 2049 Hospital 19.8 
 
65.0 ± 9.0 Hypertension 
with coronary 
artery disease 
BP measured by standard cuff 
mercury sphygmomanometer 
after 5 minutes of rest 














24hr ABPM 6.3 years Cardiovascular 
mortality 
Bjorklund [3] 872 Community 0 71 Not specified 24hr ABPM every 20 mins 6.6 ±years Cardiovascular events 
Blacher [39] 





History of CVD Twice during patient visit post 5-
minute rest 




203 Hospital 45 54.1±15.1 Hypertension Average of 3 office BP 
measurements after 10-min 
rest, 24hrs ABPM (every 15min 
daytime and every 30min 
nighttime), aortic BP monitoring 
by software analysis 
Not documented Left ventricular 
abnormalities 
Choi [40] 
1230 Hospital 44.3 59.3±12.5 
years  
Hypertension Average of 2 BP measurements 
post 10-minute rest, 24hrs 
ABPM 





6010 Hospital 51.7 71.9 ± 4.9 Hypertension At least 3 times during patient 
visit post 5-minute rest 











72±5 Hypertension 26hr ABPM every 30 mins Median: 10.9 years  Cardiovascular 
mortality and all-cause 
mortality 
Cui [33] 
998 Hospital 0 78.4±12.0 Hypertension 24hr ABPM every 15mins day, 
every 30 mins night 
Not documented Cardiovascular events 
Darabont [30] 
1975 Community 52.6 47.1±15.4 Not specified Automatic oscillometric BP 
measuring device on first clinic 
visit anytime and second clinic 
visit in morning 




1526 Community 0 58.6 years Not specified HBP at morning and evening for 
4 weeks, within 1hr after 
awakening 
12.0 years Stroke, cardiovascular 
events, cardiovascular 
mortality 
Eguchi [4] 457 Hospital 62.4 67.0±9.2 Type 2 Diabetes 24 hrs ABPM every 30 mins 67 months Cardiovascular events 
Eguchi [8] 300 Hospital 52 67.8±9.6 Not specified 24 hrs ABPM every 30 mins 54.6 months Cardiovascular events 
Eto [14] 
106 Hospital 46 73.9±8.1 Hypertension 24hrs ABPM every 30 mins Median: 34 months 
(3-60) 
Cardiovascular events 
Gao [43] 2906 Hospital 78.7  66±6.2 Not specified BP measurements from out-
patient visits 




3433 Hospital 55 56±16 Hypertension Visit-to-visit BP measured, at 
least two visits, 3 BP readings 
measured post 5 mins rest, 
24hrs ABPM every 20 mins day, 
every 20 mins night 









2865157 Hospital 6.1 59.3±13.1 
years 
Not specified Clinic BP measurements 8 years All-cause mortality, 
cardiovascular events 
Hansen [6] 
8938 Community 46.8 53 (no SD) Not specified 24hrs ABPM every 15-30 mins 
day, every 30-60 mins night 
















902 Community 0 58.6 (no SD) Not specified 24hrs ABPM every 15-30 mins 
day, every 30-60 mins night 




Hata [44] 8811 Hospital  
42 
66±6 Type 2 Diabetes Average of 2 valid BP 
measurements after a 5 mins 
rest 








65±11 History of or risk 
factors for CVD 
HBP x3, 2x morning and 1x 
evening for 14 consecutive days 
4 years Stroke, cardiovascular 
events 
Hsieh [62] 2161 Community  
57 
63.5±11.9 Type 2 Diabetes Average of 2 valid BP 
measurements after a 10-
minute rest 




1257 Community 46.8 53.1±13.1 Normotensive Two or more measurements by 
clinic sphygmomanometer and 
24hrs ABPM 




1866 Community 56.1 56.4 (no SD) Without a stroke HBP 2x, morning and evening for 
seven consecutive days 
7.8 years Cardiovascular events, 
all-cause mortality 
Kawai [45] 485 Hospital 46.8 61.7±11.5 Hypertension Average of 2 valid BP 
measurements after a 5 mins 
rest 





2455 Community 60.4 59.4±12.3 Not specified HBP every morning for 4 weeks 11.9  years All-cause mortality, 
cardiovascular 
mortality 




Hypertension Zero manometers used for 2 BP 
measurements after 5 mins of 
quiet rest 
17 years Cardiovascular 
mortality 
Lau [47] 
632 Hospital 47 71±11 Ischaemic Stroke 
without AF 
3 times during patient visit post 
5 mins rest 





656 Hospital 32 66±10 Diabetes, CVD or 
cerebrovascular 
disease 
3 times during patient visit post 
5 mins rest 







2017 Community Not 
documented 











Hypertension Average of 2 valid BP 
measurements after a 5 mins 
rest 
4.5 years Stroke 
Mena 2005 
[16] 
312 Community 63 66.9 (no SD) Hypertension 24hrs ABPM every 15 mins day, 
every 30 mins night 
1.86 years Cardiovascular events 
Mena [9] 
1254 Community 43.5 56.6 (no SD) Not specified 24hrs ABPM every 15-30 mins 
day and 30-60 mins at night 
Median: 12.4 years Cardiovascular events, 
all-cause mortality 
Mossello [5] 
100 Community 66.7 83±10 Not specified 24hrs ABPM every 15 mins day, 
every 20 mins night 
12 months All-cause mortality  
Muntner [53] 25814 Hospital Not 
documented 
>55 (no mean 
or SD) 
 
Not specified Standard BP measuring 
technique 2x by trained 
observer 




486 Hospital 46 49 (no SD) Hypertension 24hrs ABPM every 15 mins day, 
every 30 mins night 















Not specified 2 clinic BP measurements with 2 














1472 Hospital 53.1 Not 
documented 
Hypertension 24hrs ABPM every 15 mins day, 
every 30 mins night 






≥40 (no mean 
or SD) 
Hypertension 24hrs ABPM every 15 mins day, 
every 30 mins night 






5804 Hospital Not 
documented 
75.2 (no SD) History of or risk 
factors for CVD 
Clinic BP 3 years (7.1 years 






Pringle [63] 744 Community 26.7 69.5 (no SD) Not specified 24hrs ABPM every 30 mins, 
clinic BP 
4.4 years Stroke, cardiovascular 
events, cardiovascular 
mortality 
Rakugi [56] 4876 Hospital Not 
documented 
69.6±2.9 Hypertension Office BP 3.3 years Cardiovascular events 
Rothwell [57] 




Previous TIA 24hrs ABPM every 30 mins Range: 6-30 months Stroke, risk of stroke, 
cardiovascular events 
Shi [61] 
229 Hospital 31.2 66.7±13.0 Ischaemic Stroke 24hrs ABPM, standard mercury 
sphygmomanometer 
measurements every morning 
24 months Post-stroke functional 
outcome 
Shimbo [34] 58228 Hospital 100 Range: 50-79 
(no mean or 
SD)  
Not specified Average of 2 BP measurements 
after 5 mins rest, taken 30 
seconds apart 
5.4 years Stroke 
Suchy-Dicey 
[50] 
3852 Hospital 59 72±5.0 
 
Risk factors for 
CVD 
Average of 2 BP measurements 
(from a total of 3 
measurements), readings 5 mins 
apart 




Takao [58] 632 Hospital 17.8 55.7±9.3 Type 2 Diabetes Four or more BP measurements 11.1 years Cardiovascular events 
Tao [36] 
1764 Hospital 32.1 62.4±11.0 Acute ischaemic 
Stroke or TIA 
24hrs ABPM, every 15 mins 
during daytime and every 30 
mins during the night 
12 months Non-fatal recurrent 
stroke 
Veloudi [35] 286 Hospital 53 64 (no SD) Hypertension Clinic BP, 7 day HBPM, 24 ABPM 12 months Cardiovascular events 
Verdecchia 
[12] 
2649 Community 47 51 (no SD) Hypertension 24hrs ABPM every 15 mins Median: 6 years Cardiovascular events 
Wan [64] 
124105 Hospital 55.6 63.2±11.3 Type 2 Diabetes 2 clinic BP measurements with 1 
min intervals 







66±13 TIA or non-
disabling stroke 
HBP 3x3 daily for 1 week, 24hrs 
ABPM every 30 mins day and 60 
mins night 







Wei [51] 724 Community 33.1  76.6±4.6  
 
Hypertension Average of 2 BP measurements 
post 5 to 10 mins rest 







84.9 (no SD) Not specifd Day-to-day BP (total of 5-10 BP 
measurements) 
12 months All-cause mortality 
Wu [65] 
148 Community 45.4  73.3±2.8  Hypertension  Average of 2 measurements by 
clinic BP 




Yu [70] 122636 Community 54.3 64.1±11.3 Hypertension Clinic BP 48 months Stroke 
ABPM – ambulatory blood pressure measurement; AF – atrial fibulation; BP – blood pressure; CHD – coronary heart disease; CVD – cardiovascular disease; HBP – high blood 














































































































































































































































































































































































































































































































































































































Supplementary Table 4.  Summary of clinical outcomes associated with blood pressure variability. 




SD CoV ARV ALL 
Present (+) Absent (-) + - + - + - 









1 [61] 10 
[1,6,9,14,33,35,37,40,57,60] 
4 [36, 54, 61,63] 
DBP  2 [6,61]  2 
[61,61] 
2 [6,37] 2 [9,61] 2 [6,37] 2 [9,61] 
Day SBP 3 [3,11,14] 5 
[9,10,36,57,63] 
1 [14] 1 [36] 2 [9,11]  4 [3,9,11,14] 4 [10,36, 57,63] 
DBP  2 [3,11]   1 [11]  1 [11] 1 [3] 
Night SBP 5 [4,8,12,17,69] 6 
[3,9,10,11,36,63
] 
 1 [36]   5 [4,8,12,17,69] 6 
[3,9,10,11,36,63
] 
DBP 3 [8,17,69] 2 [3,11]     3 [8,17,69] 2 [3,11] 


















DBP 3 [8,17,69] 4 [3,6,11,61]  1 [61] 3 
[6,11,37] 
























SD CoV ARV ALL 
Present (+) Absent (-) + - + - + - 
24h  SBP 1 [69] 4 [2,6,16,65]   1 [6] 1 [67] 2 [6,69] 4 [2,16,65,67] 
DBP 3 [6,65,69] 2 [2,16]  1 [69*] 2 [6,67]  4 [6,65,67,69] 2 [2,16] 




DBP 3 [16,67,69] 1 [2]     3 [16,67,69] 1 [2] 
Night SBP 1 [69] 3 [2,16,67]     1 [69] 3 [2,16,67] 
DBP 1 [69] 3 [2,16,67]     1 [69] 3 [2,16,67] 
ALL SBP 2 [67,69] 4 [2,6,16,65]   1 [6] 1 [67] 3 [6,69,67] 3 [2,16,65] 
DBP 5 [6,16,65,67,69] 1 [2]  1 [69*] 2 [6,67]  5 [6,16,65,67,69] 1 [2] 
SBP/ 
DBP 




SD CoV ARV ALL 
Present (+) Absent (-) + - + - + - 
24h  SBP 1 [69] 5 
[2,16,42,52,6
5] 
 1 [15] 3 
[6,9,67] 
 4 [6,9,67,69] 6 
[2,15,16,42,52,6
5] 
DBP 3 [6,65,69] 4 [2,16,42,52]   3 
[6,9,67] 
 5 [6,9,65,67,69] 4 [2,16,42,52] 
Day SBP 2 [42,67] 3 [2,16,69]     2 [42,67] 3 [2,16,69] 
DBP 3 [16,42,67] 2 [2,69]     3 [16,42,67] 2 [2,69] 
Night SBP 2 [15,69] 5 
[2,5,16,42,67] 
    2 [15,69] 5 [2,5,16,42,67] 
DBP 3 [16,67,69] 2 [2,42]     3 [16,67,69] 2 [2,42] 
ALL SBP 4 [15,42,67,69] 5 
[2,5,16,52,65] 
 1 [15] 3 
[6,9,67] 
 6 [6,9,15,42,67,69] 5 [2,5,16, 52,65] 
DBP 6 [6,16,42,65,67,69] 2 [2,52]   3 
[6,9,67] 
 7 [6,9,16,42,65,67,69] 2 [2,52] 
SBP/ 
DBP 
7 [6,15,16,42,65,67,69] 3 [2,5,52]  1 [15] 3 
[6,9,67] 







SD CoV ARV ALL 





























6 [6,9,37,65,67,69] 5 [2,16,42,52,61] 
Day SBP 5 [3,11,14,42,67] 9 
[2,9,10,16,36,
63,61,69,57] 
1 [14] 1 [36] 2 [9,11]  6 [3,9,11,14,42,67] 7 
[2,10,16,36,57,6
3 ,69] 
DBP 4 [16,42,67,69] 35 [2,3,11]   1 [11]  5 [11,16,42,67,69] 2 [2,3] 




 1 [36]   6 [4,8,12,15,17,69] 11 
[2,3,5,9,10,11,16
,36,42,63,67] 
DBP 5 [8,16,17,67,69] 5 
[2,3,11,16,42] 
    5 [8,16,17,67,69] 5 [2,3,11,16,42] 






























































SD CoV ARV ALL 




Morning SBP 1 [20]  2 [25,68]  2 
[19,20] 
 4 [19,20,25,68]  
DBP 1 [20]    1 [20]  1 [20]  
Evening 
 
SBP  1 [20]   1 [19] 1 [20] 1 [19] 1 [20] 
DBP  1 [20]    1 [20]  1 [20] 

















DBP 3 [20,61,70] 2 [35,43] 3 
[58,61,70] 
1 [20]   4 [20,58,61,70] 2 [35,43] 
Morning -
Evening 
SBP 1 [45] 1 [20]    1 [20] 1 [45] 1 [20] 
DBP 1 [45] 1 [20]   1 [20]  2 [20,45]  
















DBP 4 [20,45,61,70] 2 [35,43] 3 
[58,70,61] 






















SD CoV ARV ALL 
Present (+) Absent (-) + - + - + - 
Morning SBP 2 [13,21]  1 [25]  1 [19]  4 [13,19,21,25]  
DBP         
Evening 
 
SBP     1 [19]    
DBP         




DBP 1 [49] 2 [48,62]  2 
[47,62
] 
  1 [49] 3 [47,48,62] 
Morning -
Evening 
SBP         
DBP         
ALL SBP 7 
[13,21,46,48,49,53,66] 




DBP 1 [49] 2 [62,48]  2 
[47,62
] 










All-cause mortality SD CoV ARV ALL  
Present (+) Absent (-) + - + - + - 
Morning SBP 3 [13,20,21] 1 [25]  2 
[19,20
] 
  3 [13,20,21] 2 [19,25] 
DBP 1 [20]    1 [20]  1 [20]  
Evening 
 
SBP  1 [20]   1 [19] 1 [20] 1 [19] 1 [20] 
DBP 1 [20]    1 [20]  1 [20]  
Daily/Visit SBP 7 
[20,49,50,53,62,64,66] 




DBP 4 [20,43,49,62] 1 [48] 1 [62] 1 [47] 1 [20]  4 [20,43,49,62] 2 [47,48] 
Morning -
Evening 
SBP 1 [20]    1 [20]  1 [20]  
DBP 1 [20]    1 [20]  1 [20]  
ALL SBP 9 
[13,20,21,62,49,50,64,
66,53] 



























CoV events & all-
cause mortality 
(day-to-day) 
SD CoV ARV ALL 
Present (+) Absent (-) + - + - + - 
Morning SBP 3 [13,20,21] 1 [25] 2 [25,68] 2 
[19,20
] 
2 [19,20]  6 [13,19,20,21,25,68]  
DBP 1 [20]    1 [20]  1 [20]  
Evening 
 
SBP  1 [20]   1 [19] 1 [20] 1 [19] 1 [20] 
DBP 1 [20]    1 [20]  1 [20]  

































SBP 2 [20,45]    1 [20]  2 [20,45]  
DBP 2 [20,45]    1 [20]  2 [20,45]  
































































SD CoV ARV ALL 































































































ABPM: ambulatory blood pressure monitoring; ARV=average real variability; CoV: coefficient of variance; DBP: diastolic blood pressure; SBP: systolic blood pressure; SD: 
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ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
Abstract 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Intro, Para 3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
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considered, language, publication status) used as criteria for eligibility, giving rationale.  
Methods, 
Eligibility Criteria 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
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Methods, Search 
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 




Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 






Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
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Extraction 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
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Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 




Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
Methods, Data 
Synthesis 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Supplementary 
Table 2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Supplementary 
Table 3 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table 1-4 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Not applicable 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Supplementary 
Table 3 




DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
Discussion, 
Paragraph 1 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
Discussion, 
Paragraph 5 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  Discussion, 
Paragraph 2-4 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 




From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The 
PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
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Systematic Review Protocol 
 
Title: Which methods of measurement of short-term blood pressure variation provide the best 
estimate of cardiovascular outcome? – a systematic review 
 
Lead Researchers: Choon-Hian Goh, Maw Pin Tan & Professor Phyo Myint 
 





Variation in blood pressure (BP) levels has long been viewed more as an obstacle to accurate blood 
pressure measurement than a risk factor itself. However, it is now accepted that variation in systolic 
and diastolic BP has a physiological basis resulting in non-random fluctuation over seconds, minutes, 
and even years of measurement, and that these changes may influence the development and 
progression of cardiovascular, cerebrovascular and renal disease (1). The heterogeneous nature of the 
existing literature makes it difficult to draw firm conclusions about the significance of variability – 
there are no standard measures or indices for any type of variation or outcomes. It is already 
acknowledged that daily variability of blood pressure can affect the diagnosis and treatment of 
hypertension on the basis of one-off office measurements, and that home and ambulatory blood 
pressure measurement may give more accurate information (2). Further, if variability proves to be a 
significant factor in cardiovascular disease, it could bring about a shift in clinical practice towards 





Measuring variability is difficult because of its close relationship with mean blood pressure, the 
influence of physical and emotional stimuli, and the frequency with which it is associated with other 
cardiovascular risk factors such as diabetes(2). Standard deviation is still frequently used to quantify 
blood pressure variation (BPV), despite the fact it only shows variation relative to the mean blood 
pressure level. New indices such as average real variability (ARV) and variation independent of the 
mean (VIM) may prove to more accurately represent the true association between BPV and 





The literature search began by hand-searching the references of a small number of high-quality papers 
in the field and reviewing their MeSH terms. These were used to construct searches for Medline and 
EMBASE databases, limiting to English, humans, and recent papers (published since 2004). The 
references of relevant reviews will also be hand-searched for appropriate papers. The titles and 
abstracts of the results will then be screened independently by two team members to produce an 
agreed-upon list of papers for full-text screen and subsequent critical appraisal.  
 
Eligibility Criteria 
Included papers will measure the effect of variability on cardiovascular outcomes such as cardiac 





Critical Appraisal Methods 
Papers will be appraised using the Cochrane risk of bias tool (4) and the CASP tool (5) where applicable.  
 
Data Analysis 
A series of study characteristics tables will help to establish the relationships between the method of 
blood pressure measurement, the index of variability used, and the results of each paper. Two 
separate tables will show the measurements and indices – these will then be cross-tabulated so that 
the magnitude of the result in each paper for each combination can be easily viewed. This will be 
followed by a meta-analysis using RevMan where feasible. Any studies which cannot be meta-analysed 
will be reported individually. 
 
Impact of Research 
 
It is hoped that following review and meta-analysis, the most effective way of measuring and 
quantifying short-term blood pressure variation for accurate prediction of cardiovascular outcomes in 
both short (≤1yr) and longer term (>1 yr) will be determined. This will help to standardise future 
research leading to a more coherent picture of blood pressure variability as a prognostic tool and as a 
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